Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin

Summary Background  Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and t...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2009-06, Vol.29 (12), p.1282-1290
Main Authors: SHERIDAN, D. A., PRICE, D. A., SCHMID, M. L., TOMS, G. L., DONALDSON, P., NEELY, D., BASSENDINE, M. F.
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - therapeutic use
Apolipoproteins B - genetics
Apolipoproteins B - metabolism
Biological and medical sciences
Cholesterol - genetics
Cholesterol - metabolism
Digestive system
Female
Gastroenterology. Liver. Pancreas. Abdomen
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - therapeutic use
Male
Medical sciences
Middle Aged
Multivariate Analysis
Pharmacology. Drug treatments
Predictive Value of Tests
Retrospective Studies
Ribavirin - therapeutic use
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background  Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides. Aim  To determine whether baseline lipid levels predicted treatment outcome. Methods  Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti‐viral agents interferon‐alpha and ribavirin; 165 had a sustained virological response (SVR). Pre‐ and post‐treatment nonfasting lipid profiles were measured and non‐high‐density lipoprotein (non‐HDL) cholesterol (i.e. apoB‐associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome. Results  There was an independent association between higher apoB‐associated cholesterol (non‐HDL‐C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non‐HDL‐C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre‐treatment non‐HDL‐C = 2.8 mmol/L, SVR = 3.6 mmol/L, P 
ISSN:0269-2813
1365-2036
DOI:10.1111/j.1365-2036.2009.04012.x